Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis

Proteomics - Clinical Applications

Volumn 4, Issue 3, 2010, Pages 304-314

  Petri, Anette Lykke ^a,b   Simonsen, Anja Hviid ^a   Høgdall, Estrid ^c   Christensen, Ib Jarle ^d   Kjaer, Susanne Krüger ^a,e   Yip, Christine ^f   Risum, Signe ^d   Pedersen, Anette Tønnes ^a   Hartwell, Dorte ^a   Fung, Eric T ^f   Høgdall, Claus ^a  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d FINSEN LABORATORY   (Denmark)

^e INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^f CIPHERGEN BIOSYSTEMS INC   (United States)

Author keywords

Biomarker; Equalizer beads; Ovarian cancer; Urine

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CANCER DIAGNOSIS; CLINICAL ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MULTIVARIATE ANALYSIS; NON INVASIVE PROCEDURE; OVARY CANCER; OVARY TUMOR; PELVIS; PRIORITY JOURNAL; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; URINALYSIS; URINE LEVEL;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROTEOMICS; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77951705317     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.200900042     Document Type: Article

References (32)

1. Jemal, A., Siegel, R., Ward, E., Murray, T. et al., Cancer statistics, 2006. CA Cancer J. Clin. 2006, 56, 106-130.
2. Schwartz, P.E., Current diagnosis and treatment modalities for ovarian cancer. Cancer Treat. Res. 2002, 107, 99-118.
3. Berchuck, A., Elbendary, A., Havrilesky, L., Rodriguez, G.C., Bast, R.C., Jr., Pathogenesis of ovarian cancers. J. Soc. Gynecol. Investig. 1994, 1, 181-190.
4. Jacobs, I.J., Menon, U., Progress and challenges in screening for early detection of ovarian cancer. Mol. Cell Proteomics 2004, 3, 355-366.
5. Boyce, E.A., Kohn, E.C., Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets. Int. J. Gynecol. Cancer 2005, 15, 266-273.
6. Annunziata, C.M., Azad, N., Dhamoon, A.S., Whiteley, G., Kohn, E.C., Ovarian cancer in the proteomics era. Int. J. Gynecol. Cancer. 2008, 18, 1-6.
7. Wilder, J.L., Pavlik, E., Straughn, J.M., Kirby, T. et al., Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol. Oncol. 2003, 89, 233-235.
8. Menon, U., Ovarian cancer screening. Oncology 2004, 171, 323-324.
9. Sturgeon, C.M., Duffy, M.J., Stenman, U.-H., Lilja, H. et al., National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin. Chem. 2008, 54, 11-79.
10. Menon, U., Gentry-Maharaj, A., Hallett, R., Ryan, A. et al., Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009, 10, 327-340.
11. Petricoin, E.F., Ardekani, A.M., Hitt, B.A., Levine, P.J. et al., Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359, 572-577.
12. Zhang, Z., Bast, R.C., Jr., Yu, Y., Li, J., et al., Three biomarkers identified from serum pro-teomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004, 64, 5882-5890.
13. Kozak, K.R., Su, F., Whitelegge, J.P., Faull, K. et al., Characterization of serum biomarker for detection of early stage ovarian cancer. Proteomics 2005, 5, 4589-4596.
14. Mor, G., Visintin, I., Lai, Y., Zhao, H. et al., Serum protein markers for early detection of ovarian cancer. Proc. Natl. Acad. Sci. USA 2005, 102, 7677-7682.
15. Chambers, A.F., Vanderhyden, B.C., Ovarian cancer biomarkers in urine. Clin. Cancer Res. 2006, 12, 323-327.
16. Ye, B., Skates, S., Mok, S.C., Horick, N.K. et al., Proteomicbased discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin. Cancer Res. 2006, 12, 432-441.
17. Petri, A.L., Simonsen, A.H., Yip, T.-T., Hogdall, E. et al., Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology. Acta Obstet. Gynecol. Scand. 2009, 88, 18-26.
18. Høgdall, E., Fung, E.T., Zhang, Z., Engelholm, S.A. et al., Prospective independent validation of a marker panel for distinguishing benign from malignant pelvic masses. Abstracts Presented for the 38th Annual Meeting of the Society of Gynecologic Oncologists, 38th Annual Meeting on Women's Cancer. Gynecol. Oncol. 2007, 104 (3 pt 1), 37.
19. Petri, A.L., Kjaer, S.K., Christensen, I.J., Blaakaer, J. et al., Validation of epithelial ovarian cancer and Fallopian tube cancer and ovarian borderline tumor data in the Danish Gynecological Cancer Database. Acta Obstet. Gynecol. Scand. 2009, 88, 536-542.
20. Kafali, H., Artunc, H., Erdem, M., Evaluation of factors that may be responsible for cyclic change of CA125 levels during menstrual cycle. Arch. Gynecol. Obstet. 2007, 275, 175-177.
21. Moore, R.G., Brown, A.K., Miller, M.C., Skates, S. et al., The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol. Oncol. 2008, 108, 402-408.
22. Visintin, I., Feng, Z., Longton, G., Ward, D.C. et al., Diagnostic markers for early detection of ovarian cancer. Clin. Cancer Res. 2008, 14, 1065-1072.
23. Kumar, S., Tsai, C.J., Nussinov, R., Temperature range of thermodynamic stability for the native state of reversible two-state proteins. Biochemistry 2003, 42, 4864-4873.
24. Marshall, T., Williams, K. Two-dimensional electrophoresis of human urinary proteins following concentration by dye precipitation. Electrophoresis 1996, 17, 1265-1272.
25. Pieper, R., Gatlin, C.L., McGrath, A.M., Makusky, A.J. et al., Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on twodimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics 2004, 4, 1159-1174.
26. Thongboonkerd, V., Chutipongtanate, S., Kanlaya, R., Systematic evaluation of sample preparation methods for gel-based urinary proteomics: quantity, quality, and variability. J. Proteome Res. 2006, 5, 183-191.
27. Thongboonkerd, V., Proteomic analysis of renal diseases: unravelling the pathophysiology and biomarker discovery. Expert Rev. Proteomics 2005, 2, 349-366.
28. Papale, M., Pedicillo, M.C., Thatcher, B.J., Di Paolo, S. et al., Urine profiling by SELDI-TOF/MS: monitoring of the critical steps in sample collection, handling and analysis. J. Chromatogr. 2007, 856, 205-213.
29. Hortin, G.L., Sviridov, D., Diagnostic potential for urinary proteomics. Pharmacogenomics 2007, 8, 237-255.
30. Twardowski, T., Fertala, A., Orgel, J.P., San Antonio, J.D., Type I collagen and collagen mimetics as angiogenesis promoting superpolymers. Curr. Pharm. Des. 2007, 13, 3608-3621.
31. Kjellev, S., The trefoil factor family - small peptides with multiple functionalities. Cell Mol. Life Sci. 2009, 66, 1350-1369.
32. Skates, S.J., Horick, N., Yu, Y., Xu, F. -J et al., Pre-operative sensitivity and specificity for early stage ovarian cancer when combining CA125, CA 15.3, CA 72.4 and M-CSF using mixtures of multivariate normal distributions. J. Clin. Oncol. 2004, 22, 4059-4066.